explore -WSS

explore

author：leisure time 2025-09-28 02:27:53 - browse：79

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law, the Food and Drug Administration’s move could give doctors an avenue to prescribe the medications to some Medicare patients.

Wegovy’s new label indicates that the drug can be used to reduce the risk of major heart complications for people who are overweight or obese and have existing heart disease, Novo said in a statement Friday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Prosecutors say FTX founder Sam Bankman

WSS

Hey, doctors: Don't be no

Listen: BridgeBio's big week & Lilly's Alzheimer's data

Prosecutors say FTX founder Sam Bankman

Would Medicare drug price negotiations stall in a shutdown?

Listen: Who gets the credit for GLP

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Wikipedia

explore

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

State Dept. review finds Biden bears some blame for Afghanistan failures

Biden White House, tech companies launch new safeguards around emerging AI technology

Virginia high school admissions case could be legal follow

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

How to save PrEP access — and even expand it

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

The cancer drug shortage isn’t new — and neither are the solutions

Medicaid, Medicare dual

hotspot

Researchers use wearables data and AI to predict preterm birth risk

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Shingles, which affected Dianne Feinstein, is on the rise

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

Sudafed saga points to U.S. issues with evaluating older drugs

knowledge

knowledge

knowledge

focus